文献速递垂体与肾上腺疾病

18F-FDG PET/CT扫描在肾上腺肿瘤定性中的诊断价值

The Diagnostic Value of 18F-FDG PET/CT Scan in Characterizing Adrenal Tumors.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该荟萃分析评估18F-FDG PET/CT鉴别肾上腺肿瘤良恶性的诊断价值,纳入17项研究。汇总敏感度为87.3%(95%CI 82.5%-90.9%),特异度为84.7%(95%CI 79.3%-88.9%),诊断比值比为9.20(95%CI 5.27-16.08;P<.01)。作者认为其诊断准确性良好,但文献有限,尤其关于肾上腺偶发瘤,需大规模前瞻性研究。

要点

  • 18F-FDG PET/CT鉴别肾上腺肿瘤良恶性的汇总敏感度为87.3%,特异度为84.7%。
  • 汇总诊断比值比为9.20(95%CI 5.27-16.08;P<.01)。
  • 异质性主要来源为人群特征、参考标准和影像结果判读标准。

核心结论

  • 18F-FDG PET/CT对肾上腺肿瘤定性具有良好诊断准确性。
  • 相关文献有限,尤其是关于肾上腺偶发瘤的文献。
  • 需要在定义明确的人群中应用经过验证的截断值开展大规模前瞻性研究。

研究设计与样本

  • 研究类型为荟萃分析,检索PubMed、EMBASE、Web of Science和Cochrane Library中2000年至2021年的文章。
  • 纳入描述18F-FDG PET/CT在成人肾上腺肿瘤患者中诊断价值的研究。
  • 排除标准为参与者10例或更少、组织病理学、临床随访或PET结果数据不充分的研究。
  • 经2名独立审稿人筛选标题和摘要后检索到79项研究,其中17项符合选择标准。
  • 至少2名作者独立使用协议提取数据,并根据QUADAS-2进行质量评估,采用R(版本3.6.2)的双变量随机效应模型进行数据合成。

主要发现

  • 18F-FDG PET/CT识别恶性肾上腺肿瘤的汇总敏感度为87.3%(95%CI 82.5%-90.9%),汇总特异度为84.7%(95%CI 79.3%-88.9%)。
  • 汇总诊断比值比为9.20(95%CI 5.27-16.08;P<.01)。
  • 异质性主要来源(I2=57.1%[95%CI 27.5%-74.6%])为人群特征、参考标准和影像结果判读标准。

关键数值与推荐

  • 18F-FDG PET/CT识别恶性肾上腺肿瘤的汇总敏感度为87.3%(95%CI 82.5%-90.9%)。
  • 18F-FDG PET/CT识别恶性肾上腺肿瘤的汇总特异度为84.7%(95%CI 79.3%-88.9%)。
  • 汇总诊断比值比为9.20(95%CI 5.27-16.08;P<.01)。
  • 异质性I2=57.1%(95%CI 27.5%-74.6%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 文献有限,尤其是关于肾上腺偶发瘤的文献。
  • 需要在定义明确的人群中应用经过验证的截断值开展大规模前瞻性研究。
  • 异质性主要来源(I2=57.1%[95%CI 27.5%-74.6%])为人群特征、参考标准和影像结果判读标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Imaging plays an important role in the characterization of adrenal tumors, but findings might be inconclusive. The clinical question is whether 18F fluodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) is of diagnostic value in this setting. OBJECTIVE: This meta-analysis was aimed at the diagnostic value of 18F-FDG PET/CT in differentiating benign from malignant adrenal tumors discovered either as adrenal incidentaloma or during staging or follow-up of oncologic patients. DATA SOURCES: PubMed, EMBASE, Web of Science, and Cochrane Library were searched to select articles between 2000 and 2021. STUDY SELECTION: We included studies describing the diagnostic value of 18F-FDG PET/CT in adult patients with an adrenal tumor. Exclusion criteria were 10 or fewer participants, insufficient data on histopathology, clinical follow-up, or PET results. After screening of title and abstract by 2 independent reviewers, 79 studies were retrieved, of which 17 studies met the selection criteria. DATA EXTRACTION: Data extraction using a protocol and quality assessment according to QUADAS-2 was performed independently by at least 2 authors. DATA SYNTHESIS: A bivariate random-effects model was applied using R (version 3.6.2.). Pooled sensitivity and specificity of 18F-FDG PET/CT for identifying malignant adrenal tumors was 87.3% (95% CI, 82.5%-90.9%) and 84.7% (95% CI, 79.3%-88.9%), respectively. The pooled diagnostic odds ratio was 9.20 (95% CI, 5.27-16.08; P < .01). Major sources of heterogeneity (I2, 57.1% [95% CI, 27.5%-74.6%]) were in population characteristics, reference standard, and interpretation criteria of imaging results. CONCLUSIONS: 18F-FDG PET/CT had good diagnostic accuracy for characterization of adrenal tumors. The literature, however, is limited, in particular regarding adrenal incidentalomas. Large prospective studies in well-defined patient populations with application of validated cutoff values are needed.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Schaafsma M, Berends AMA, Links TP, et al. The Diagnostic Value of 18F-FDG PET/CT Scan in Characterizing Adrenal Tumors. J Clin Endocrinol Metab. 2023. PMID: 36948598. doi:10.1210/clinem/dgad138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。